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PI4KAA functional screen of an adenovirus-delivered shRNA library that targets ∼4500 host genes was performed
to identify cellular factors that regulate hepatitis C virus (HCV) sub-genomic RNA replication. Seventy-three
hits were further examined by siRNA oligonucleotide-directed knockdown, and silencing of the PI4KA gene
was demonstrated to have a signiﬁcant effect on the replication of a HCV genotype 1b replicon. Using
transient siRNA oligonucleotide transfections and stable shRNA knockdown clones in HuH-7 cells, the PI4KA
gene was shown to be essential for the replication of all HCV genotypes tested (1a, 1b and 2a) but not
required for bovine viral diarrhea virus (BVDV) RNA replication.
© 2009 Elsevier Inc. All rights reserved.IntroductionIt is estimated that about 3% of the human population is infected
with hepatitis C virus (HCV). This corresponds to about 170 million
individuals, most of whom are chronically infected (World Health
Organization, 1999). The currently approved therapy for chronic HCV
infection is a combination of pegylated-interferon α and ribavirin.
Unfortunately, this treatment has only a 50–80% efﬁcacy depending on
the HCV genotype. In addition, signiﬁcant side effects are often
observed and account for a high discontinuation rate (Deutsch and
Hadziyannis, 2008). Several drugs that target a limited number of viral
proteins are in preclinical and clinical development.
Therapies that target viral proteins may result in varying pan-
genotype efﬁcacies due to the high degree of HCV sequence variation.
The search for anti-viral therapies that target host proteins would
complement current discovery efforts and may potentially lead to the
identiﬁcation of compounds that are broadly active against all
genotypes. In addition, therapies that target host proteins may provide
greater barriers to drug-resistance. Several cellular cofactors involved in
HCV replication, infection and pathogenesis have been described in
previous studies (He et al., 2007; Randall et al., 2007; Ng et al., 2007;
Supekova et al., 2008; de Chassey et al., 2008); only 3 of these involvedngelheim.com
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ll rights reserved.broad screening of targets. In one study, about 4000 genes that are
potential targets for drug discovery (mostly protein kinases, G-coupled
receptors and ion channels) were screened using siRNAs (Ng et al.,
2007). In a second study, 510 human genes (mostly protein kinases)
were tested in a similar fashion (Supekova et al., 2008). Another
alternative approach used the yeast two-hybrid system to identify
interactions betweenhuman andHCVproteins (de Chassey et al., 2008).
In an effort to expand the identiﬁcation of host factors that regulate
HCV RNA replication, we describe the use of a library of adenoviral
vector-delivered shRNAs to screen over 4500 human drugable
transcripts (Arts et al., 2003). The initial hits from this screen were
conﬁrmed using siRNA oligonucleotide transfection, and a consistent
target that encoded for a host cell lipid kinase was further validated as
an essential host factor for HCV RNA replication.
Results and discussion
Screening of a HCV sub-genomic replicon cell line with an adenoviral
shRNA library
The SilenceSelect™ library expresses small hairpin RNAs (shRNAs)
that target ∼4500 select human genes in up to three-fold redundancy
by encoding two to three distinct shRNAs complementary to speciﬁc
regions for each host cellular gene target. The effect of adenovirus-
encoded shRNA knockdown on HCV 1b sub-genomic RNA replication
was indirectly monitored by measuring HCV replicon luciferase
activity and by directly measuring sub-genomic RNA levels by real-
time qRT-PCR. Positive controls represented by adenoviruses encoding
Fig. 1. SilenceSelect™ adenovirus shRNA screen to identify genes involved in HCV RNA
replication. (A) The effect of 420 selected shRNA adenoviruses on the inhibition of the
primary HCV 1b replicon luciferase signal and related HCV RNA levels; a slope of 0.74, a
y-intersection of 0.08 and a R2 of 0.42 reﬂect the correlation between HCV replicon
inhibition by real-time qRT-PCR and the replicon-encoded luciferase signal. Only the
adenoviruses with positive signals in both assays are shown in this ﬁgure. (B) Target
class distribution for the 154 possible loci as targets for inhibition of HCV RNA
replication. (C) Distribution of the sub-cellular localization for the 154 possible loci as
targets for inhibition of HCV RNA replication.
6 Rapid CommunicationshRNAs that target speciﬁc regions of the sub-genomic replicon
(either NS5B or the luciferase gene), as well as negative controls that
included empty vector or non-speciﬁc shRNA sequences, were
identiﬁed as suitable comparators and were included on each of the
library screening plates. A total of 11 268 different shRNA-encoding
adenoviruses were tested in duplicate and the ability of these
adenoviruses to inhibit HCV 1b sub-genomic replicon luciferase levels
was monitored. The screening results had a broad distribution with a
mean inhibition of 24% and a large standard deviation of ±37% that
reﬂected thewide spectrum of activities demonstrated by the samples
of the library. Four hundred and twenty hits that demonstrated ≥85%
inhibition were identiﬁed and selected for conﬁrmation studies (3.7%
of the library).
The 420 adenoviral-encoded shRNAs were tested at an average MOI
of 250 in the luciferase-based HCV replicon cell-based assay and by
directly measuring sub-genomic RNA levels by real-time qRT-PCR (Fig.
1A). One hundred and forty-three adenoviruses that demonstrated
≥80% inhibition in the HCV genotype 1b replicon qRT-PCR assay were
conﬁrmed as inhibitors; an additional 20 adenoviruses that demon-
strated≥60% inhibition in the qRT-PCR assay at an MOI of less than 200
were also retained. A total of 163/420 adenoviruses were conﬁrmed as
inhibitors, representing a conﬁrmation rate of nearly 40%.
Modulation of HCV 1b sub-genomic replicon activity was tested in
an adenovirus “MOI-dependent” manner for all of the conﬁrmed 163
adenoviruses by generating response curves through serial viral
dilutions with the EC50 represented as the dilution titer for each
shRNA adenovirus required to achieve 50% inhibition of HCV replicon
luciferase signal (i.e. EC50 in MOI values). The 163 adenoviruses that
inhibit HCV RNA replication demonstrated EC50 values that ranged
from 6 to 250 MOI, and for 27 of these adenoviruses, the EC50 values
were estimated because the curves did not reach an Emax. Eight
adenoviruses demonstrated an EC50N250 MOI and two adenoviruses
were targeting loci discontinued in GenBank. These ten adenoviruses
were not pursued further.
Analyses of the 153 positive hits and MOI-response curves
demonstrated that one adenovirus was targeting two genes (TPSAB1
and TPSB2). The screen therefore identiﬁed 154 possible loci as targets
for inhibition of HCV 1b replication (Supplementary Table 1). These
154 possible loci encompassed 12 different target classes (Fig. 1B) and
the sub-cellular localization of these targets is very diverse (Fig. 1C).
Only two of the conﬁrmed hits identiﬁed in this screen were
previously described in the literature (He et al., 2007; Randall et al.,
2007; Ng et al., 2007; Supekova et al., 2008; de Chassey et al., 2008) as
host cell factors associated with HCV replication: SLC12A5 had
previously been identiﬁed in an siRNA screen (Ng et al., 2007),
whereas the PI4KA gene product was characterized as an interactor
with HCV proteins (de Chassey et al., 2008; Ahn et al., 2004). Different
screening libraries, different delivery systems, as well as variations
between HuH-7 cells or adaptive mutations in the sub-genomic
replicon may contribute to the minimal overlap between the different
HCV siRNA knockdown studies. Notably, the comparison of three
different siRNA screens that were performed to identify host genes
involved in HIV replication (Brass et al., 2008; König et al., 2008; Zhou
et al., 2008) found little pair-wise overlap among the hit sets. This
may, in part, be attributable to differences in experimental conditions
(Goff, 2008). Furthermore, it was noted that the presence of false
positive hits is very likely, which reinforces the necessity for further
target validation of the most interesting hits (Goff, 2008).
siRNA oligonucleotide knockdown
siRNA oligonucleotides were obtained for 132 of the 154 targets
and their effect on the luciferase signal of the HCV 1b replicon was
evaluated (Supplementary Table 1) following transient transfection.
Based on bioinformatics evaluation and dose-dependent effect on
replicon luciferase activity, the knockdown by 73 siRNA
Table 1
Evaluation of adenovirus shRNA and siRNA oligonucleotide for HCV replicon inhibition
for the 73 hits that were evaluated by qRT-PCR.
Gene
symbol
RefSeq Adenovirus
targeting
siRNA targeting
EC50 (MOI)a Luciferase
inhibition
(%)
HCV replicon
inhibition
evaluated by
qRT-PCR (%)
Host
transcript
inhibition
evaluated by
qRT-PCR (%)
ABCB10 NM_012089 55 36 (9) −2 (21) 81 (1)
ABHD5 NM_016006 80 17 (5) −3 (5) 87 (1)
ABHD6 NM_020676 85 −55 (24) 3 (14) 89 (6)
ACVRL1 NM_000020 55 63 (6) 44 (10) 82 (5)
AEBP1 NM_001129 130 22 (17) 12 (8) 69 (8)
AKAP13 NM_006738 87 3 (24) 13 (11) 68 (3)
BMP2 NM_001200 75 −6 (6) −19 (9) 62 (2)
CACNB2 NM_000724 38 −25 (13) −12 (17) 61 (5)
CAPN10 NM_021251 60 52 (3) 25 (5) Undet.
CH25H NM_003956 120 34 (7) 53 (4) Undet.
CPB1 NM_001871 58 39 (20) 43 (3) 87 (2)
CPZ NM_001014447 41 −39 (20) −9 (17) Undet.
CRHR2 NM_001883 88 −37 (5) −3 (13) Undet.
CTRL NM_001907 90 42 (3) 25 (12) 87 (3)
CXCR4 NM_001008540 110 30 (7) −14 (12) 61 (5)
DHX30 NM_014966 64 37 (15) 40 (5) 80 (2)
DLG5 NM_004747 67 −40 (4) −68 (15) 59 (4)
DOK4 NM_018110 70 4 (12) −2 (1) 76 (1)
DUSP23 NM_017823 110 −17 (18) −60 (42) Undet.
FLJ25006 NM_144610 82 −135 (30) −69 (14) Undet.
FUT4 NM_002033 91 −32 (15) −29 (13) 8 (15)
GDF7 NM_182828 28 24 (17) 24 (13) 72 (6)
GLS2 NM_013267 99 −50 (9) −38 (16) 67 (9)
GPD2 NM_000408 85 −29 (11) 17 (10) 93 (1)
GSG2 NM_031965 53 30 (10) 9 (18) 69 (7)
HADH NM_005327 98 31 (23) 45 (2) 93 (1)
HNF4G NM_004133 67 −3 (15) 18 (4) 88 (3)
HSD11B2 NM_000196 88 33 (6) 18 (6) 39 (3)
HTRA4 NM_153692 93 2 (16) −6 (20) Undet.
IKBKB NM_001556 100 15 (10) 19 (10) 65 (3)
ITGA8 NM_003638 79 −3 (15) −14 (11) Undet.
KALRN NM_001024660 83 30 (6) −27 (11) 45 (6)
KCNF1 NM_002236 92 74 (5) 60 (9) Undet.
KLK10 NM_001077500 97 44 (2) 14 (6) Undet.
LEPREL2 NM_014262 99 36 (7) 13 (11) 70 (4)
LGI2 NM_018176 73 0 (5) 1 (19) 95 (1)
LYPLA3 NM_012320 33 25 (5) 23 (8) 68 (3)
MGC16169 NM_033115 78 −27 (13) −9 (9) 55 (2)
MGLL NM_001003794 6.4 −40 (8) −16 (4) 94 (1)
MTHFD1 NM_005956 58 10 (7) 13 (16) 91 (1)
MTMR7 NM_004686 52 −92 (11) −50 (9) 80 (2)
NNMT NM_006169 130 12 (7) −46 (26) 97 (1)
OXER1 NM_148962 39 −30 (11) −22 (15) 46 (7)
PARP1 NM_001618 83 −15 (30) 21 (6) 97 (1)
PHEX NM_000444 77 4 (7) −41 (26) 79 (2)
PI4KA NM_002650 29 98 (1) 95 (1) 83 (1)
PLA2G2A NM_000300 120 41 (4) 32 (22) Undet.
PRDX6 NM_004905 55 −18 (23) 2 (16) 90 (1)
PRKCG NM_002739 88 17 (12) 32 (8) 28 (16)
PRKCZ NM_001033581 35 39 (6) 40 (5) 68 (4)
PRODH2 NM_021232 61 62 (5) 45 (6) 62 (6)
PRSS22 NM_022119 150 29 (9) 13 (4) 65 (5)
PSMA4 NM_001102667 59 −33 (19) −115 (26) 85 (2)
PTGER4 NM_000958 76 −1 (12) 2 (16) 47 (9)
PTPN4 NM_002830 97 29 (6) 18 (13) 54 (3)
RPE NM_006916 72 −18 (7) 15 (11) 76 (2)
SDHA NM_004168 100 38 (6) 43 (9) 90 (1)
SLC12A5 NM_020708 89 48 (6) 34 (5) 31 (12)
SLC35A5 NM_017945 95 −64 (24) −36 (11) 91 (2)
SLC41A3 NM_001008485 87 62 (5) 51 (5) 89 (1)
SNF1LK2 NM_015191 61 30 (6) 23 (8) 0 (4)
SPPL2B NM_001077238 40 −1 (8) 4 (4) 53 (5)
SPTLC2 NM_004863 94 62 (4) 52 (12) 90 (3)
SV2B NM_014848 84 44 (8) 23 (10) Undet.
SYK NM_003177 Undet. −49 (29) −67 (14) Undet.
TAOK1 NM_020791 60 22 (9) 30 (6) 72 (1)
TNFRSF10B NM_003842 19 14 (13) 17 (10) 65 (2)
TNFSF13B NM_006573 40 −85 (29) −53 (15) 71 (1)
Table 1 (continued)
Gene
symbol
RefSeq Adenovirus
targeting
siRNA targeting
EC50 (MOI)a Luciferase
inhibition
(%)
HCV replicon
inhibition
evaluated by
qRT-PCR (%)
Host
transcript
inhibition
evaluated by
qRT-PCR (%)
TPST1 NM_003596 99 −4 (10) −1 (3) 77 (2)
TRPV4 NM_021625 49 57 (6) 50 (3) 52 (2)
TRPV6 NM_018646 64 68 (2) 58 (6) Undet.
XPNPEP1 NM_020383 67 −54 (22) −26 (10) 82 (1)
XYLT2 NM_022167 120 10 (21) 39 (5) 87 (1)
Values in parentheses represent standard deviations. Negative values correspond to an
increase in HCV replication.
a Titer dilution of each shRNA adenovirus required for 50% inhibition of luciferase
signal from the replicon.
7Rapid Communicationoligonucleotides was further evaluated for the level of inhibition of
cellular gene expression and HCV 1b replication by real-time qRT-PCR
(Table 1; Fig. 2). The majority of host transcripts were knocked-down
by greater than 50%, but showed a less than proportional inhibition of
HCV RNA replication. Knocked-down targets that displayed propor-
tional inhibition of HCV RNA replication were considered for further
validation studies. The lipid kinase PI4KIIIα (PI4KA gene target),
demonstrated a signiﬁcant level of inhibition of HCV 1b replication
upon knockdown of transcript levels and was prioritized for further
validation.
Validation of PI4KA as a key factor involved in HCV replication
In addition to HCV genotype 1b, the effect of siRNA targeting of
PI4KA was also investigated with genotypes 1a, 2a as well as bovine
viral diarrhea virus (BVDV) sub-genomic replicons. The knockdown of
PI4KA speciﬁcally inhibited cross-genotype HCV replication, including
replication of the unadapted genotype 2a JFH-1 clone, whereas no
effect on BVDV replication was observed (Fig. 3A). PI4KA stable
knockdown clones were generated in the HuH-7 (Fig. 3B) and HuH-
7.5 cell lines; these lines had an average 1 log10 reduction in levels of
PI4KA transcript. Transient transfection of HCV 1b replicon RNA in
these cell lines resulted in a minimum of 97% inhibition of HCV 1b
replication relative to control cell lines and more than 3-log10
inhibition relative to the parental HuH-7.5 cells. This level of HCV
inhibition, ranging from −1.5 to −3 log10 relative to both parental
and sub-clones further validates a role for this target (Fig. 3D). The
inhibition of stable replication was more pronounced in HuH-7.5-Fig. 2. Identiﬁcation of PI4KA as a host factor for HCV 1b RNA replication. The effect of
siRNA knockdown on cellular RNA transcripts and HCV RNA replicon levels was
determined by TaqMan real-time qRT-PCR for the 73 hits selected for further analysis.
Only the hits with positive signals in both assays are shown in this ﬁgure. Due to the
clustering of data points, error bars were removed from all but the PI4KA sample.
Fig. 3. Validation of PI4KA as an essential host factor in HCV RNA replication. (A) siRNA oligonucleotide-directed knockdown of PI4KA speciﬁcally inhibits cross-genotype HCV RNA
replication. Data for HCV replicon genotype 1b is illustrated in blue, genotype 1a in pink, genotype 2a in yellow and BVDV in green. The siRNA targeting of replicon-encoded luciferase
(siHCV-Luc) is presented as a positive control. (B) The stability of PI4KA RNA transcript suppression observed in a stable HuH-7 shRNA PI4KA knockdown clone. The control HuH-7
cell line is shown in blue (closed triangles) and the HuH-7 PI4KA stable knockdown clone that expresses an shRNA targeting the 3′-end of the PI4KA gene is shown in orange (open
squares). (C) HuH-7.5 cells and derived stable clones transfected with HCV 1b replicon RNA. Cells were electroporatedwith 5 μg of puriﬁed bicistronic, neomycin-phosphotransferase
encoding HCV1b replicon RNA that was synthesized in vitro using T7 RiboMAX™ Express Large Scale RNA Production System (Promega). The selection processwas initiated after 72 h
using medium supplemented with G-418 (0.5 mg/ml) and puromycin (3 μg/ml); colonies were visible after 3 weeks and stained with crystal violet. Upper plate: HuH-7.5, middle
plate: HuH-7.5 stable clone with an shRNA targeting hMGFP (control), lower plate: HuH-7.5 stable clone with an shRNA targeting the 5′-end of PI4KA. (D) Luciferase levels obtained
after transient transfection of the HCV 1b luciferase replicon RNA in stable PI4KA knockdown clones and control cell lines. Five micrograms of puriﬁed in vitro transcribed HCV1b
replicon RNAwas electroporated in the different cell lines and luciferase levels were determined at 4, 72 and 96 h post-transfection; values are corrected for transfection efﬁciency by
measuring the signal at 4 h and expressing the luciferase levels as a percentage of this time point. The HuH-7.5 cell line is shown in dark blue (closed diamonds). A stable HuH-7.5
clonewith an shRNA targeting GFP (control) is shown in pink (closed square). The HuH-7 cell line is shown in blue (closed triangles). Three different HuH-7 stable knockdown clones
with an shRNA targeting the 3′-end of the PI4KA gene are shown in green (open diamonds), orange (open squares) and black (closed circles). A HuH-7.5 stable knockdown clonewith
an shRNA targeting the 3′-end of the PI4KA gene is shown in gray (open circles) and a HuH-7.5 stable knockdown clone with an shRNA targeting the 5′-end of the PI4KA gene is
shown in brown (open triangles). As a negative control, the HuH-7 cell line transfected with a replication-incompetent HCV1b replicon (NS5B D318A/D319A) is shown in red (closed
squares). (E) Luciferase levels obtained after transfection of the BVDV replicon in HuH-7 and HuH-7 stable PI4KA knockdown clones. Five micrograms of puriﬁed in vitro transcribed
BVDV transcripts was electroporated in the different cell lines (color coded as described in panel D) and relative luciferase levels were determined as described above. As a negative
control, the HuH-7 cell line transfected with a replication-incompetent BVDV replicon (NS5B D448A/D449A) is shown in purple (closed square).
8 Rapid Communicationderived knockdown clones, in which no HCV 1b replicon resistant to
PI4KA knockdown could be selected (Fig. 3C). The transfection of
BVDV replicons in the same stable cell lines demonstrated that PI4KA
knockdown had no effect on BVDV replication (Fig. 3E).
In order to determine if PI4KA is the only gene fromphosphoinositide
metabolism to be involved in HCV 1b replication, all other known
phosphoinositide lipid kinases and phosphatidylinositol-4-phosphate
phosphatases (Vicinanza et al., 2008) were targeted by siRNA, and their
effect on HCV replicon-dependent luciferase activity was determined.
None demonstrated any signiﬁcant effect on HCV 1b replication (data
not shown). The PI4KA gene appears to be the only member of the
phosphoinositidemetabolism family that plays a role inHCV replication.
Conclusion
PI4KA, which encodes the PI4KIIIα protein, is a potentially
interesting target required for HCV RNA replication. Notably, thisenzymewas also identiﬁed in a yeast two-hybrid study using a portion
of the HCVNS5A protein as a bait (Ahn et al., 2004) and the amino acid
region 1799–1916 of PI4KIIIα is proposed to interact with domain II–III
of NS5A (aa 300–447). The precise role of PI4KIIIα in HCV replication
may be through protein–protein interactions with NS5A and/or the
product of its kinase activity. Although further mechanistic studies are
required to elucidate its precise role, the inhibition of this host target
may provide for effective anti-viral HCV therapy.
Materials and methods
Culture and cell lines
DMEM High glucose (Wisent Inc.) supplemented with 10% fetal
bovine serum (FBS; HyClone) containing neomycin (250 μg/ml)
(Geneticin; Invitrogen) was used as growth medium and DMEM High
glucose+10% FBS without neomycin was used as the assay medium.
9Rapid CommunicationThe viral sub-genomic replicons that were used are bicistronic
constructs encoding the HCV1b, HCV1a, HCV2a or BVDV-NADL non-
structural genes in one cistron and the reporter ﬁreﬂy-luciferase-
FMDV2a-neomycin-phosphotransferase gene fusion in the upstream
cistron (Beaulieu et al., 2006). The HCV1a, HCV2a and BVDV replicons
were transfected into HuH-7 cells and the HCV1b replicon was
transfected into either the HuH-7 or HuH-7.5 cells (Blight et al., 2002).
Stable PI4KA knockdownHuH-7 andHuH-7.5 cloneswere generated
using the siSTRIKE™ Human U6 Hairpin cloning systems with a
puromycin selectable marker (Promega). The Promega siRNA Target
Designer was used for selection of target sequences and for the design
of hairpin oligonucleotides. Plasmid transfections were performed with
Lipofectamine™ LTX Reagent following the supplier's protocol (Invitro-
gen). Medium was supplemented with 3 μg/ml puromycin to initiate
the selection process. Two different shRNA sequences that target the 3′-
end (target sequence: 5′-GGTCATATCATCCACATC-3′) or the 5′-end
(target sequence: 5′-AAGCTAAGCCTCGGTTAC-3′) of PI4KA were used
and an shRNA targeting hMGFP (target sequence: 5′-CCGTGAACGGC-
CACAAAT-3′; Promega) was used as a control shRNA.
Assay optimization and screening using SilenceSelect™ adenoviral
library
Optimal assay conditions established for screening included the
plating of 7500 HCV replicon 1b cells/well, adenovirus shRNA at 250
MOI, followed by incubation for 144 h and the quantiﬁcation of
luciferase signal using the “Luciferase assay system” (Promega). The
positive control was an adenoviral vector encoding an shRNA tar-
geting the HCV1b NS5B (target sequence: 5′-CACTGAGACACCAATT-
GAC-3′), whereas the negative control consisted of an adenoviral
vector harboring a scrambled version of NS5B target sequence (5′
TCAGTCAGCTAATCACACC-3′). The same protocol was implemented
for dose–response curves, except that 9 serial dilutions (1:2) in assay
medium were prepared for each shRNA adenovirus. The starting
dilutionwas 250 MOI and the last dilution evaluated was 0.5 MOI. The
luciferase results and MOI values for each shRNA adenovirus were
analyzed by SAS nonlinear regression and an EC50 value (expressed as
an MOI value that provides for 50% inhibition in luciferase signal) was
obtained for individual shRNA adenoviruses.
siRNA oligonucleotide transfection
All siRNA oligonucleotides used to knockdown cellular genes were
siGENOME or ON-TARGETplus SMARTpool® siRNA reagents from
Dharmacon RNAi Technologies (Thermo Scientiﬁc). The transfection
agent was DharmaFECT™ 4 from Dharmacon RNAi Technologies
(Thermo Scientiﬁc) and Opti-MEM I Reduced Serum Medium
(Invitrogen) was used to dilute siRNA and DharmaFECT™ 4. siRNA
oligonucleotides (10 nM) were transfected (according to Dharma-
FECT™ 4 transfection protocol; Thermo Scientiﬁc) 24 h after seeding
10 000 cells/well in assay medium in 96-well plates. One hundred
hours post-transfection, the luciferase signal was determined and/or
the RNA was isolated for real-time qRT-PCR determination.
RNA isolation from cells and quantiﬁcation
The “RNeasy 96 kit” (Qiagen) was used to isolate RNA from cells.
The total RNA concentration was determined using the “RiboGreen®
RNA Quantitation Kit” from Molecular Probes. The RNA concentration
of the samples was determined from the standard curve generated
using the ribosomal RNA standards.
Real-time qRT-PCR assays
The “TaqMan EZ RT-PCR kit” (Applied Biosystems; ABI) was used to
perform RT-PCR reactions on a 7500 Real Time PCR System (ABI). Forthe quantiﬁcation of HCV replicon RNA, the detection of the neomycin-
phosphotransferase gene was performed using the following forward
and reverse primers: 5′-CCG GCT ACC TGC CCA TTC-3′; 5′-CCA GAT
CAT CCT GAT CGA CAA G-3′. The probe used was 5′(FAM)-ACA TCG
CAT CGA GCG AGC ACG TAC-(TAMRA) 3′ (Integrated DNA Technolo-
gies). The Ct values obtained for the RNA assay samples were used to
interpolate an RNA replicon (copy) number based on the standard
curve, and the RNA replicon (copy) number was normalized (by
RiboGreen RNA quantiﬁcation of the RNA extracted from cells) and
expressed as quantity of replicon/μg of total RNA. The quantiﬁcation of
cellular RNA transcripts was achieved with the “TaqMan® Gene
Expression Assays” (ABI) containing gene-speciﬁc probes and primer
sets. Serial dilutions of untreated cellular HuH-7 RNA were used to
generate a standard for each gene-speciﬁc expression analysis and to
determine relative changes in transcript levels.
Bioinformatic analyses
Information about all 154 hits was primarily obtained from NCBI
Gene (http://www.ncbi.nlm.nih.gov/) and NetAffx™ Analysis Center
(http://www.affymetrix.com/analysis/index.affx). The cellular loca-
lization shown was found in the GO cellular component associated
with each gene.
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